Burke Steven Keith 4
4 · Akebia Therapeutics, Inc. · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
Akebia (AKBA) CMO Steven Burke Sells Shares
What Happened
Steven Keith Burke, SVP and Chief Medical Officer of Akebia Therapeutics (AKBA), disposed of a total of 67,658 shares on 2026-02-02 in three open-market sales at $1.39 per share, totaling roughly $94,045. The filing shows the sales were either made under a pre-arranged trading plan (Rule 10b5-1) or were automatic "sell-to-cover" transactions to satisfy tax withholding on vesting restricted stock units.
Key Details
- Transaction date and price: 2026-02-02, $1.39 per share.
- 21,582 shares sold for $29,999
- 25,375 shares sold for $35,271
- 20,701 shares sold for $28,774
- Total shares sold: 67,658; approximate proceeds: $94,045.
- Shares owned after transaction: not reported in the supplied filing details.
- Footnotes:
- F1 — One sale pursuant to a Rule 10b5-1 trading plan adopted Nov 17, 2023.
- F2–F4 — Other sales were automatic issuer sell-to-cover transactions to cover tax withholding on vesting/settlement of one-third portions of RSUs granted Jan 31, 2023; Jan 31, 2024; and Jan 31, 2025.
- Filing: Report filed 2026-02-04 for transactions on 2026-02-02; appears to be timely (filed within standard Form 4 window).
- Transaction code: S = Sale; F = tax withholding/sell-to-cover.
Context
Sales executed under a Rule 10b5-1 plan and automatic sell-to-cover transactions for tax withholding are common and typically routine administrative actions rather than explicit signals about an insider’s view of the company. This filing is informational; it does not by itself indicate insider sentiment or future company performance.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-02-02$1.39/sh−21,582$29,999→ 994,508 total - Sale
Common Stock
[F1][F3]2026-02-02$1.39/sh−25,375$35,271→ 969,133 total - Sale
Common Stock
[F1][F4]2026-02-02$1.39/sh−20,701$28,774→ 948,432 total
Footnotes (4)
- [F1]This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2023.
- [F2]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023.
- [F3]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024.
- [F4]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025.